Literature DB >> 11093147

Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity.

H Nakajima1, M Cella, A Bouchon, H L Grierson, J Lewis, C S Duckett, J I Cohen, M Colonna.   

Abstract

Patients with the X-linked lymphoproliferative disorder (XLPD) are unable to control Epstein-Barr virus (EBV)-induced infections and lymphoproliferation. This disease is caused by a deficit of SAP, an adapter protein involved in the signal transduction of several cell surface receptors of the CD2 superfamily. One of these receptors, called 2B4, is expressed on NK cells, cytotoxic T cells and myeloid cells and activates NK cell cytotoxicity. Here we show that XLPD patients have a defect of 2B4 receptor-mediated NK cell cytotoxicity. This defect may contribute to the pathogenesis of XLPD by reducing NK cell lysis of EBV-infected B cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093147     DOI: 10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  40 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function.

Authors:  Mario-Ernesto Cruz-Munoz; Zhongjun Dong; Xiaochu Shi; Shaohua Zhang; André Veillette
Journal:  Nat Immunol       Date:  2009-01-18       Impact factor: 25.606

3.  Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells.

Authors:  Zhongjun Dong; Mario-Ernesto Cruz-Munoz; Ming-Chao Zhong; Riyan Chen; Sylvain Latour; André Veillette
Journal:  Nat Immunol       Date:  2009-08-02       Impact factor: 25.606

Review 4.  Up on the tightrope: natural killer cell activation and inhibition.

Authors:  Lewis L Lanier
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

5.  Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus.

Authors:  J R Kim; S O Mathew; R K Patel; R M Pertusi; P A Mathew
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

Review 6.  Recognition of tumors by the innate immune system and natural killer cells.

Authors:  Assaf Marcus; Benjamin G Gowen; Thornton W Thompson; Alexandre Iannello; Michele Ardolino; Weiwen Deng; Lin Wang; Nataliya Shifrin; David H Raulet
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 7.  XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.

Authors:  Feng-Yen Li; Benjamin Chaigne-Delalande; Helen Su; Gulbu Uzel; Helen Matthews; Michael J Lenardo
Journal:  Blood       Date:  2014-02-18       Impact factor: 22.113

8.  EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Authors:  Deirdre O'Mahony; John C Morris; Maryalice Stetler-Stevenson; Helen Matthews; Margaret R Brown; Thomas Fleisher; Stefania Pittaluga; Mark Raffeld; Paul S Albert; Dirk Reitsma; Karen Kaucic; Luz Hammershaimb; Thomas A Waldmann; John E Janik
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

Review 9.  X-linked lymphoproliferative disease (XLP): a model of impaired anti-viral, anti-tumor and humoral immune responses.

Authors:  Hamid Bassiri; W C Janice Yeo; Jennifer Rothman; Gary A Koretzky; Kim E Nichols
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

10.  Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family.

Authors:  C Alejandro Velikovsky; Lu Deng; Lukasz K Chlewicki; Marisa M Fernández; Vinay Kumar; Roy A Mariuzza
Journal:  Immunity       Date:  2007-10-18       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.